Skip to main content

Table 5 Post-hoc analysis treatment arm C1 with regard to SVR

From: The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive individuals

  SVR No SVR p-value
  n = 21 n = 28  
Age [years] 41 (31 - 47) 42 (27 - 47) 0.732
Male sex [%] 81 71 0.733
Transmission risk IVDU [%] 19 29 0.844
HCV genotype 1 or 4 [%] 43 79 0.007
HCV-RNA [IU/ml, log10]    
    HCV-RNA ≥ 500 000 IU/ml [%] 5.1 (4 - 6) 5.7 (4.7 - 7.2) 0.001
  24 54 0.019
ALT [IU/l] 72 (31 - 206) 71 (27 - 243) 0.949
Weight adapted RBV, GT 1/4 infections only [%] 100 68 0.141
Tx duration 48 wks, GT 2/3 infections only [%] 42 20 0.600
    Enrollment period 2002 - 2004 [%] 52 57 0.771
HAART [%]
    3 × NRTI 10 14 0.688
    AZT 24 39 0.359
    d4T 19 18 1.000
    ABC 19 39 0.210
    TDF 52 43 0.572
HIV-RNA > Lod [%] 4 14 0.369
CD4-cellcount [/μl] 470 (268 - 685) 524 (222 - 781) 0.521
Elevations serum ALT [%]
    Grade 1/2 76 79 1.000
    Grade 3/4 - 11 0.250
Anemia [%]
    Grade 1/2 24 21 1.000
    Grade 3/4 - - -
Leucopenia [%]    
    Grade 1/2 57 61 1.000
    Grade 3/4 14 11 1.000
Thrombocytopenia [%]
    Grade 1/2 57 46 0.567
    Grade 3/4 9 11 1.000
Clinical adverse events [%]
    Grade 1/2 67 61 0.769
    Grade 3/4 10 7 1.000
Dose reduction PegIFN [%]† 10 18 0.436
    % of total dose received 87 81  
Dose reduction RBV [%]† 14 32 0.179
    % of total dose received 91 78  
Treatment discont. AEs [%] - 14 0.125
  1. †Percent of patients who were dose reduced for pegylated interferon (PegIFN) or ribavirin (RBV) and respective percent of the cumulative dose received.
  2. Data shown as percent of patients (95% Confidence Interval) or median (95% range). SVR sustained virological response, IVDU intravenous drug abuse, ALT serum alanine aminotransferase, RBV ribavirin, GT HCV genotype, Tx Treatment, wks weeks, NRTI nucleos(t)ide reverse transcriptase inhibitor, AZT zidovudine, d4T stavudine, ABC abacavir, TDF tenofovir DF, Lod Level of detection, Treatment discont. AEs Treatment discontinuation due to adverse events.